Praxis Precision Medicines, Inc.

NasdaqGS:PRAX Stock Report

Market Cap: US$8.5b

Praxis Precision Medicines Management

Management criteria checks 2/4

Praxis Precision Medicines' CEO is Marcio De'Souza, appointed in Apr 2020, has a tenure of 5.92 years. total yearly compensation is $13.43M, comprised of 4.8% salary and 95.2% bonuses, including company stock and options. directly owns 0.085% of the company’s shares, worth $7.24M. The average tenure of the management team and the board of directors is 4.8 years and 4.4 years respectively.

Key information

Marcio De'Souza

Chief executive officer

US$13.4m

Total compensation

CEO salary percentage4.77%
CEO tenure5.9yrs
CEO ownership0.09%
Management average tenure4.8yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Praxis: Priced For Perfection Heading Into 2026

Dec 31

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Jul 18
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Apr 04
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Mar 04

Praxis Precision Medicines: Multiple Potential Drivers

Dec 26

Praxis Precision Medicines: Great Price Movement, But Still Not Convinced

Oct 13

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26

CEO Compensation Analysis

How has Marcio De'Souza's remuneration changed compared to Praxis Precision Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$303m

Sep 30 2025n/an/a

-US$273m

Jun 30 2025n/an/a

-US$251m

Mar 31 2025n/an/a

-US$213m

Dec 31 2024US$13mUS$640k

-US$183m

Sep 30 2024n/an/a

-US$151m

Jun 30 2024n/an/a

-US$124m

Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$625k

-US$123m

Sep 30 2023n/an/a

-US$138m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$183m

Dec 31 2022US$6mUS$625k

-US$214m

Sep 30 2022n/an/a

-US$231m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$208m

Dec 31 2021US$11mUS$571k

-US$167m

Sep 30 2021n/an/a

-US$135m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021n/an/a

-US$88m

Dec 31 2020US$12mUS$385k

-US$70m

Compensation vs Market: Marcio's total compensation ($USD13.43M) is above average for companies of similar size in the US market ($USD8.15M).

Compensation vs Earnings: Marcio's compensation has increased whilst the company is unprofitable.

CEO

Marcio De'Souza (45 yo)

5.9yrs
Tenure
US$13,427,668
Compensation

Mr. Marcio Silva De'Souza M.B.A., has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in...

Leadership Team

NamePositionTenureCompensationOwnership
Marcio De'Souza
President5.9yrsUS$13.43m0.085%
$ 7.2m
Timothy Kelly
CFO & Treasurer4.8yrsUS$4.04m0.032%
$ 2.7m
Alex Nemiroff
General Counsel & Secretary5.8yrsUS$3.92m0.024%
$ 2.0m
Steven Petrou
Co-Founder and President of Research & Developmentno datano datano data
Megan Sniecinski
Chief Operating Officerless than a yearno data0.032%
$ 2.7m
Karl Hansen
Chief Technical Operations Officer4.3yrsno datano data
Kelly McCue
Chief People Officer5.3yrsno data0.013%
$ 1.1m
Alyssa J. Wyant
Chief Regulatory & Quality Officer5.5yrsno datano data
Brian Spar
Chief of Staff4yrsno datano data
Orrin Devinsky
Head of Clinical Strategyless than a yearno datano data
4.8yrs
Average Tenure
47.5yo
Average Age

Experienced Management: PRAX's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marcio De'Souza
President5.9yrsUS$13.43m0.085%
$ 7.2m
William Young
Independent Director9.3yrsUS$361.44k0.0068%
$ 578.5k
Dean Mitchell
Independent Chairman of the Board5.5yrsUS$388.98k0.062%
$ 5.3m
Gregory Norden
Independent Director7yrsUS$368.32k0.00068%
$ 57.8k
Merit Cudkowicz
Independent Director4.9yrsUS$360.27k0%
$ 0
Jill DeSimone
Independent Director3.8yrsUS$363.73k0.0035%
$ 294.8k
Jeffrey Chodakewitz
Independent Director4.9yrsUS$356.27k0%
$ 0
Anna Greka
Member of Scientific Advisory Board3.2yrsno datano data
Matthew Might
Chairman of the Scientific Advisory Board3.2yrsno datano data
Holger Lerche
Member of Scientific Advisory Board3.2yrsno datano data
Ivan Soltesz
Member of Scientific Advisory Board3.2yrsno datano data
Samuel Berkovic
Member of Scientific Advisory Board3.2yrsno datano data
4.4yrs
Average Tenure
69yo
Average Age

Experienced Board: PRAX's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/17 19:39
End of Day Share Price 2026/03/17 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Praxis Precision Medicines, Inc. is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joel BeattyBaird
null nullBaird